231 related articles for article (PubMed ID: 10618581)
1. Neurohormonal modulation in cardiovascular disease.
Unger T
Am Heart J; 2000 Jan; 139(1 Pt 2):S2-8. PubMed ID: 10618581
[TBL] [Abstract][Full Text] [Related]
2. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
Carnovali M
Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
[TBL] [Abstract][Full Text] [Related]
3. The renin-angiotensin system and its receptors.
Stroth U; Unger T
J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S21-8; discussion S41-3. PubMed ID: 10028950
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
Wolf G; Ritz E
Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
[TBL] [Abstract][Full Text] [Related]
5. [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
Sandmann S; Unger T
Drugs; 2002; 62 Spec No 1():43-52. PubMed ID: 12036388
[TBL] [Abstract][Full Text] [Related]
6. The role of the renin-angiotensin system in the development of cardiovascular disease.
Unger T
Am J Cardiol; 2002 Jan; 89(2A):3A-9A; discussion 10A. PubMed ID: 11835903
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
8. Cardiac protection: evolving role of angiotensin receptor blockers.
Califf RM; Cohn JN
Am Heart J; 2000 Jan; 139(1 Pt 2):S15-22. PubMed ID: 10618583
[TBL] [Abstract][Full Text] [Related]
9. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Pfeffer MA
Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
[TBL] [Abstract][Full Text] [Related]
10. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
Li XC; Zhang J; Zhuo JL
Pharmacol Res; 2017 Nov; 125(Pt A):21-38. PubMed ID: 28619367
[TBL] [Abstract][Full Text] [Related]
11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
12. Presence of functional angiotensin II receptor and angiotensin converting enzyme in the aorta of the snake Bothrops jararaca.
Esteves CA; Burckhardt PL; Breno MC
Life Sci; 2012 Nov; 91(19-20):944-50. PubMed ID: 23000029
[TBL] [Abstract][Full Text] [Related]
13. [Angiotensin II receptor blockers: current status and future prospects].
Corvol P; Plouin PF
Drugs; 2002; 62 Spec No 1():53-64. PubMed ID: 12036389
[TBL] [Abstract][Full Text] [Related]
14. The Interplay between the Renin Angiotensin System and Pacing Postconditioning Induced Cardiac Protection.
Babiker F; Al-Jarallah A; Joseph S
PLoS One; 2016; 11(11):e0165777. PubMed ID: 27814397
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders.
Stanton A
Am J Cardiovasc Drugs; 2003; 3(6):389-94. PubMed ID: 14728059
[TBL] [Abstract][Full Text] [Related]
16. Combination of ACE inhibitors and calcium antagonists: a logical approach.
Ruschitzka FT; Noll G; Lüscher TF
J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
[TBL] [Abstract][Full Text] [Related]
17. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease.
Brunner HR
Am J Cardiol; 2001 Apr; 87(8A):3C-9C. PubMed ID: 11334762
[TBL] [Abstract][Full Text] [Related]
18. Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists.
Meyer P; Flammer J; Lüscher TF
Invest Ophthalmol Vis Sci; 1995 Mar; 36(3):555-62. PubMed ID: 7890486
[TBL] [Abstract][Full Text] [Related]
19. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors.
Janke J; Engeli S; Gorzelniak K; Luft FC; Sharma AM
Diabetes; 2002 Jun; 51(6):1699-707. PubMed ID: 12031955
[TBL] [Abstract][Full Text] [Related]
20. Cardiac remodelling and RAS inhibition.
Ferrario CM
Ther Adv Cardiovasc Dis; 2016 Jun; 10(3):162-71. PubMed ID: 27105891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
